Skip Ribbon Commands Skip to main content
Help (new window)
University of Balamand > Academics > Research > Seminars > Mazin Moufarij

Combination Chemotherapy in Chronic Lymphocytic Leukemia (CLL)

Thursday, May 17, 2007 from 12:30 to 13:30 at Jacobo Auditorium

SUBMITTED BY: Dr. Mazin Moufarij
Faculty of Medicine
University of Balamand

ABSTRACT: Chronic lymphocytic leukemia (CLL) is the most frequent type of leukemia in Western countries and it accounts for approximately 25 % of all Leukemias. CLL is characterized by the accumulation of long-lived mature-appearing B lymphocytes. At present there is no curative treatment. Alkylating agents and nucleoside analogues are two classes of anticancer agents important in the treatment of chronic lymphocytic leukemia. Indolent B-cell malignancies such as CLL exhibit a high DNA damage repair capacity. Knowledge of this biological property provides a rationale for therapeutic strategies that combine DNA-damaging cytotoxic agents, such as oxaliplatin, with an inhibitor of DNA repair such as fludarabine. Our research studies and findings provided the basis for a phase I, II study of a novel combination chemotherapy regimen in patients with Richter’s transformation, prolymphocytic leukemia and refractory/relapsed B-CLL
​​
facebook    LinkedIn    youTube    Social Media
University of Balamand,
Balamand Al Kurah,
Lebanon

Tel:  +961-6-930250
Fax: +961-6-930278